Your Health, We Care
On October 24, 2025, Syndax Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved Revuforj (generic name: revumenib) for the treatment of adult and pediatric patients with relapsed or refractory acute myeloid leukemia harboring an NPM1 gene mutation.
On November 15, 2024, the U.S. Food and Drug Administration (FDA) approved Revuforj (generic name: revumenib) for the treatment of adult and pediatric patients with relapsed or refractory acute leukemia with a KMT2A gene translocation.
On June 24, 2025, Syndax Pharmaceuticals announced that the U.S. Food and Drug A···【more】
Release date：2026-01-28Recommended：13
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy originating from ···【more】
Release date：2026-01-28Recommended：14
Recently, Syndax Pharmaceuticals announced additional positive data from the AUG···【more】
Release date：2026-01-28Recommended：14
